Antibacterial Eliminates Recurrence of C. Difficile Infections in Phase II - Labiotech.eu
MGB Biopharma's antibacterial treatment for Clostridium difficile infections cured 100% of the patients, who showed no recurrence four weeks after.
C Diff Drug Development
Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium - BioSpace
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that it will present new data from its SER-109 Phase 3 ECOSPOR III clinical study that confirm the intended pharmacological properties of this investigational microbiome therapeutic for recurrent C. difficile infection (CDI).
The C Diff Foundation Assures Patients C. diff. Clinical Trials Continue to Move Forward Safely - Northwest Georgia News
TAMPA, Fla., Jan. 11, 2021 (SEND2PRESS NEWSWIRE) –- While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to
Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology - Valdosta Daily Times
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 6, 2021--
Destiny Pharma completes enrolment for XF-73 trial on schedule - Proactive Investors UK
XF-73 has been awarded both qualifying infectious disease product and Fast Track status by the US Food and Drug Administration
Microbome for c diff works
An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.
Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficile infections
Brighton, United Kingdom – 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical d...